Dna X (SONM) Equity Ratio (2018 - 2026)

Dna X has reported Equity Ratio for 9 years, with the latest figure at 0.2 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 577.11% year-over-year to 0.2; the trailing twelve-month figure through Mar 2026 stood at 0.2 (down 577.11% YoY), and the FY2025 full-year result was 0.18, down 26.34% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.2, down from 0.18 in the prior quarter.
• The five-year high for Equity Ratio was 0.47 in Q1 2024, with the low at 0.2 in Q1 2026.
• Historically, Equity Ratio has averaged 0.2 across 5 years, with a median of 0.31 in 2024.
• Annual changes were most pronounced in 2023 — Equity Ratio soared 114.24% — and 2026, when it slumped 577.11%.
• Dna X's Equity Ratio stood at 0.37 in 2022, then increased by 6.9% to 0.4 in 2023, then plunged by 135.94% to 0.14 in 2024, then fell by 26.34% to 0.18 in 2025, then declined by 12.12% to 0.2 in 2026.
• The last three Equity Ratio figures came in at 0.2 (Q1 2026), 0.18 (Q4 2025), and 0.02 (Q3 2025), per Business Quant data.